Ginkgo Bioworks Holdings (DNA) Free Cash Flow (2020 - 2026)

Ginkgo Bioworks Holdings has reported Free Cash Flow for 7 years, with the latest figure at -$48.4 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 18.22% year-over-year to -$48.4 million; the trailing twelve-month figure through Mar 2026 stood at -$167.9 million (up 51.36% YoY), and the FY2025 full-year result was -$178.7 million, up 53.23% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$48.4 million, down from -$47.7 million in the prior quarter.
• The five-year high for Free Cash Flow was -$23.5 million in Q1 2022, with the low at -$146.8 million in Q4 2022.
• Historically, Free Cash Flow has averaged -$73.5 million across 5 years, with a median of -$61.3 million in 2023.
• Annual changes were most pronounced in 2023 — Free Cash Flow tumbled 368.63% — and 2025, when it jumped 73.35%.
• Ginkgo Bioworks Holdings' Free Cash Flow stood at -$146.8 million in 2022, then jumped by 58.26% to -$61.3 million in 2023, then gained by 8.38% to -$56.1 million in 2024, then climbed by 15.07% to -$47.7 million in 2025, then decreased by 1.43% to -$48.4 million in 2026.
• The last three Free Cash Flow figures came in at -$48.4 million (Q1 2026), -$47.7 million (Q4 2025), and -$31.6 million (Q3 2025), per Business Quant data.